News & Updates
Filter by Specialty:

Nivolumab bests ipilimumab in head-to-head melanoma trial
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
Young-onset diabetes: Novel insights on management
At EmW 2025, Professor Andrea Luk from the Department of Medicine & Therapeutics, the Chinese University of Hong Kong, shared insights and recommendations on management of young-onset diabetes (YoD).
Young-onset diabetes: Novel insights on management
28 Oct 2025
HK data: LAI antipsychotics superior to oral antipsychotics in older patients with schizophrenia
Long-acting injectable (LAI) antipsychotics are associated with lower risks of disease relapse and mortality than oral antipsychotics in older patients with schizophrenia, a population-based study in Hong Kong has shown.
HK data: LAI antipsychotics superior to oral antipsychotics in older patients with schizophrenia
28 Oct 2025
Soft drinks may fuel depression via gut microbiome
Consumption of soft drinks predicts major depressive disorder (MDD) diagnosis and symptom severity in women through gut microbiota alterations, a cohort study has shown.





